GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rain Oncology Inc (NAS:RAIN) » Definitions » Shiller PE Ratio

Rain Oncology (Rain Oncology) Shiller PE Ratio : (As of May. 17, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Rain Oncology Shiller PE Ratio?

Rain Oncology does not have a history long enough to calculate E10. Therefore GuruFocus does not calculate Shiller PE Ratio for this company.

Shiller PE for Stocks: The True Measure of Stock Valuation


Rain Oncology Shiller PE Ratio Historical Data

The historical data trend for Rain Oncology's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rain Oncology Shiller PE Ratio Chart

Rain Oncology Annual Data
Trend Dec19 Dec20 Dec21 Dec22
Shiller PE Ratio
- - - -

Rain Oncology Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Rain Oncology's Shiller PE Ratio

For the Biotechnology subindustry, Rain Oncology's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Rain Oncology's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Rain Oncology's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Rain Oncology's Shiller PE Ratio falls into.



Rain Oncology Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Rain Oncology does not have a history long enough to calculate E10. Therefore GuruFocus does not calculate Shiller PE Ratio for this company.


Rain Oncology  (NAS:RAIN) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Rain Oncology Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Rain Oncology's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Rain Oncology (Rain Oncology) Business Description

Traded in Other Exchanges
N/A
Address
8000 Jarvis Avenue, Suite 204, Newark, CA, USA, 94560
Rain Oncology Inc is a late-stage precision oncology company developing therapies that target oncogenic drivers for which it is able to genetically select patients it believes will likely benefit. This approach includes using a tumor-agnostic approach to select patients based on their tumors' underlying genetics rather than histology. The company's product candidate, milademetan, is a small molecule, oral inhibitor of MDM2, which is oncogenic in numerous cancers. In addition to milademetan, the company is also developing a preclinical program that is focused on inducing synthetic lethality in cancer cells by inhibiting RAD52.
Executives
Kevin C Tang 10 percent owner 4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121
Josephine Bruce officer: Principal Fin. & Acc. Officer 8000 JARVIS AVENUE, SUITE 204, NEWARK CA 94560
Tang Capital Partners Lp 10 percent owner 4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121
Tang Capital Management Llc 10 percent owner 4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121
Boxer Capital, Llc other: See remarks. 12860 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
Boxer Asset Management Inc. other: See remarks CAY HOUSE, EP TAYLOR DRIVE N7776, LYFORD CAY, NEW PROVIDENCE C5 00000
Joseph Lewis other: See remarks. PO BOX N7776, LYFORD BAHAMAS
Aaron I. Davis director 12860 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
Erik Atkisson officer: General Counsel and CCO C/O EIGER BIOPHARMACEUTICALS, INC., 2155 PARK BLVD., PALO ALTO CA 94306
Franklin M Berger director 1000 MARINA BLVD, STE 200, BRISBANE CA 94005
Biotechnology Value Fund L P other: See Explanation of Responses 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Avanish Vellanki director, officer: President and CEO 8000 JARVIS AVENUE, SUITE 204, NEWARK CA 94560
Perceptive Life Sciences Master Fund Ltd 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Cormorant Asset Management, Lp 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Gorjan Hrustanovic director C/O KYMERA THERAPEUTICS, INC., 200 ARSENAL YARDS, SUITE 230, WATERTOWN MA 02472

Rain Oncology (Rain Oncology) Headlines